qHTS for inhibitors of the NTHi Toxin VapC-1

NTHi 毒素 VapC-1 抑制剂的 qHTS

基本信息

批准号：
9359862
负责人：
Matthew Hall
金额：
$ 3.75万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9359862
关键词：
Anti-Bacterial Agents Antibiotics Bacteria Bacterial Proteins Biological Assay Biology Chemicals Collaborations Communities Development Disease Extramural Activities Fostering General Population Genomics Goals Infection Informatics Lead Modeling Pharmaceutical Chemistry Pharmaceutical Preparations Process Proteins Publications Research Research Personnel Resources Synthesis Chemistry Toxin United States National Institutes of Health Validation Work assay development base drug development drug discovery high throughput screening human disease improved inhibitor/antagonist new technology novel therapeutics screening small molecule small molecule therapeutics therapeutic development tool

Anti-Bacterial Agents Antibiotics Bacteria Bacterial Proteins Biological Assay Biology Chemicals Collaborations Communities Development Disease Extramural Activities Fostering General Population Genomics Goals Infection Informatics Lead Modeling Pharmaceutical Chemistry Pharmaceutical Preparations Process Proteins Publications Research Research Personnel Resources Synthesis Chemistry Toxin United States National Institutes of Health Validation Work assay development base drug development drug discovery high throughput screening human disease improved inhibitor/antagonist new technology novel therapeutics screening small molecule small molecule therapeutics therapeutic development tool

展开

项目摘要

During this period, the team worked to adapt and optimize an HTS-amenable VapC assay in 1536-well format to enable small molecule screening. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

在此期间，团队致力于以1536孔格式适应和优化HTS无效的VAPC测定法，以实现小分子筛选。作为一个中心，NCGC与NIH和壁外研究人员培养并维持了110多次积极合作，从而促进了整个人类疾病范围内的药物发现工作。这些努力导致了数十个高通量屏幕和许多药物化学运动，以进一步改善筛选效果，为我们的合作者和一般研究社区提供出版物以及各种有希望的小分子探测器和铅。此外，NCGC努力促进许多信息计划，以更好地利用现有的药物和疾病目标信息，并为公众提供易于获得的资源，从而进一步促进针对人类疾病的新疗法的发展。